Advaxis Inc
Most Recent
Company & Industry Overviews.Why Investors Are Excited about Advaxis
Advaxis (ADXS), in collaboration with Merck (MRK), is conducting a Phase 1 Part 2 trial to evaluate the safety and efficacy of ADXS-PSA.
Company & Industry Overviews.FDA Lifts Hold on Clinical Trial: Major Boost for Advaxis
In a major development, Advaxis announced on July 13 that the FDA has lifted its hold on the IND (Investigational New Drug) application.
Company & Industry Overviews.Why Advaxis Stock Is Soaring Today
Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.
Company & Industry Overviews.XBI Recovers from Its Slump
The SPDR S&P Biotech ETF (XBI) and the iShares Nasdaq Biotechnology ETF (IBB) were the top biotechnology ETFs last week, returning 5.3%, and 3.7%.
Company & Industry Overviews.Advaxis Led the Bottom Ten Biotechnology Stocks by Market Cap
Advaxis (ADXS), which has a weight of 0.61% in the SPDR S&P Biotechnology (XBI) ETF, rose 24.54% for the week ended September 11, 2015.